Antibody-Mediated Osseous Regeneration for Bone Tissue Engineering in Canine Segmental Defects

A. Khojasteh, S. Hosseinpour, M. M. Dehghan, F. Mashhadiabas, M. Rezai Rad, S. Ansari, S. Farzad Mohajeri, and H. H. Zadeh

1School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Students’ Research Committee, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
5Institute of Biomedical Research, University of Tehran, Tehran, Iran
6Oral and Maxillofacial Pathology, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7Dental Research Center, Research Institute of Dental Sciences, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8University of California, Los Angeles, CA, USA
9Laboratory for Immunoregulation and Tissue Engineering (LITE), Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA

Correspondence should be addressed to A. Khojasteh; arashkhojasteh@yahoo.com and H. H. Zadeh; zadeh@usc.edu

Received 16 August 2017; Revised 16 December 2017; Accepted 16 January 2018; Published 28 February 2018

Academic Editor: Weijie Fu

Copyright © 2018 A. Khojasteh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Among many applications of therapeutic monoclonal antibodies (mAbs), a unique approach for regenerative medicine has entailed antibody-mediated osseous regeneration (AMOR). In an effort to identify a clinically relevant model of craniofacial defect, the present study investigated the efficacy of mAb specific for bone morphogenetic protein (BMP)-2 to repair canine segmental mandibular continuity defect model. Accordingly, a 15 mm unilateral segmental defect was created in mandible and fixated with a titanium plate. Anorganic bovine bone mineral with 10% collagen (ABBM-C) was functionalized with 25 \( \mu \)g/mL of either chimeric anti-BMP-2 mAb or isotype-matched mAb (negative control). Recombinant human (rh) BMP-2 served as positive control. Morphometric analyses were performed on computed tomography (CT) and histologic images. Bone densities within healed defect sites at 12 weeks after surgery were 1360.81 ± 10.52 Hounsfield Unit (HU), 1044.27 ± 141.16 HU, and 839.45 ± 179.41 HU, in sites with implanted anti-BMP-2 mAb, rhBMP-2, and isotype mAb groups, respectively. Osteoid bone formation in anti-BMP-2 mAb (42.99% ± 8.67) and rhBMP-2 (48.97% ± 2.96) groups was not significantly different but was higher (\( p < 0.05 \)) than in sites with isotype control mAb (26.8% ± 5.35). In view of the long-term objective of translational application of AMOR in humans, the results of the present study demonstrated the feasibility of AMOR in a large clinically relevant animal model.

1. Introduction

Bone repair encompasses a cascade of biological processes that require progenitor cells, appropriate signaling molecules, and suitable scaffold [1]. Administration of bioactive molecules such as growth factors [2, 3] and cytokines [4] can mediate bone regeneration by driving stem cell into osteogenic differentiation. Growth factor therapy has been utilized for bone tissue engineering with promising results by application of osteoinductive exogenous growth factors including BMPs, fibroblast growth factor (FGF), transforming growth factor-beta (TGF-\( \beta \)), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), and vascular growth factor (VEGF) [5–9]. BMP family as a member of TGF-\( \beta \) superfamily [10] consists of over 20 identified members, not all of which have osteoinductive function [11]. BMPs initiate
BMP/TGF-β signaling pathways that culminate in osteogenesis [12, 13]. Recombinant human (rh) BMP-2 and BMP-7 [14] have been approved for specific indications of skeletal repair by US Food and Drug Administration (FDA) [15]. Application of BMPs showed bone formation initiation [16], stem cells differentiation and migration [16, 17], and promotion of bone volume [18, 19], area [20], calcium content [21], and mechanical strength [22]. BMP-2 plays a significant role in BMP and Wnt signaling and is essential for inherent capacity of bone healing [23–25]. In addition, application of exogenous rhBMP-2 has been demonstrated to initiate the bone regeneration cascade through the BMP/TGF-β pathway [26, 27].

Notwithstanding the positive osteogenic effects of rhBMP-2 clinical application, such strategy has a number of drawbacks that limit this mode of therapy as the definitive solution. Specifically, recombinant growth factors have lower activity than endogenous counterparts, unsustainable concentration over time, and short in vivo half-life [28–32], necessitating the clinical dosage, which is several orders of magnitude greater than the physiologic dose. The extremely high dose has been attributed to growing concerns about biological complications, such as increased malignancy risk [33] and potentially life-threatening edema. A practical disadvantage of administering high dosage of protein required achieving the desired clinical response; the cost is proportionally high [34].

Hence, alternative therapeutic approaches such as gene therapy [35], protein therapy [36–38], and antibody therapy [39–41] have been proposed to overcome these limitations. Moreover, antibody-mediated osseous regeneration (AMOR) technique has been documented as an alternative to the application of exogenous rhBMP-2. This principle is based on an approach to use specific monoclonal antibodies (mAb) such as anti–BMP-2 to capture endogenous BMPs to mediate bone regeneration [42]. Previous studies indicated AMOR as a promising alternative in bone tissue engineering in vitro and in vivo [39, 42–48]. In critical sized calvarial defects in rat and rabbit models, complete repair has been observed after 6–8 weeks [39, 42–48] and similar defect among rabbits showed significant increased amount of new bone formation after 45 days [45]. It is essential to investigate the influences in larger models due to mimicking the actual clinical conditions [49]. In the present study, we created segmental mandibular defects in canine models.

The main objective of this study was to investigate the feasibility of applying chimeric anti-BMP-2 mAbs for AMOR used in segmental mandibular defects of canine models for bone regeneration.

2. Materials and Methods

2.1. Reagents. Anorganic bovine bone mineral with 10% collagen (ABBM-C; Bio-Oss-Collagen, Geistlich Pharma, Wolhusen, Switzerland) was used as the scaffold in AMOR. ABBM has interconnected macropores to allow for neovascularization and bone cell infiltration and micropores to allow for fluid exchange, as well as nanostructure to help with osteogenesis [50]. Chimeric anti-BMP-2 mAb recently developed in our laboratory [47] was used in this study. The negative control consisted of isotype-matched mAb (Iso, anti-rabbit IgG2a mAb, Biovision, Mountain View, CA) with no specific affinity to BMP-2. Anti-BMP-2 mAb and its isotype-matched control mAb were diluted with phosphate-buffered saline (PBS) at 25 μg/mL concentration. Recombinant human BMP-2 (Infuse, Medtronic, Inc., Memphis, TN, USA) was used at 20 μg/ml as positive control. Scaffolds were incubated with 250 μl of diluted anti-BMP-2 mAb (total of 6.25 μg), isotype-matched mAb (total of 6.25 μg), or rhBMP-2 (total of 5.0 μg), as previously described [42].

2.2. Animals. Nine male mongrel dogs with average weight of 14–22 kg, aged 1–2 years, were used in this study. This experiment was approved by Institutional Animal Care and Use Committee (IACUC) of the Shahid Beheshti University of Medical Sciences and conformed to standards of the Association for Assessment and Accreditation of Laboratory Animal Care. The animals were kept for 2 weeks to become acclimatized to housing and diet. Animals were vaccinated and treated by antifungal drugs by staff veterinarian. During the study, animal well-being was monitored by examining activity, general appearance, and weight. They were fed soft food (Friskies, Purina, Marne La Vallee, France).

2.3. Surgical Procedure. Systemic (ketamine hydrochloride, Ketavel, 5 mg/kg body weight) and local anesthesia (2% lidocaine with 1:80,000 epinephrine) were administered. Mandibular body was exposed by an extraoral submandibular incision (Figure 1(a)). Prior to creating defects, one 9-hole titanium reconstruction plate was adapted to the inferior border of mandibular buccal side in order to keep mandible in appropriate position. The plate was secured via titanium screws. To create a segmental defect of 15 mm width in the mandibular fourth premolar tooth (PM4) on right side of each mandible [51] plate and screws were removed temporarily. After the resection, they were repositioned (Figure 1(b)). The surgical region was copiously irrigated with sterile saline solution. The animals were randomly divided into three groups of 3 dogs each: (A) Bio-Oss collagen + anti-BMP-2 mAb (25 μg/mL), (B) Bio-Oss collagen + rhBMP-2 (20 μg/mL), and (C) Bio-Oss collagen + isotype-matched mAb (25 μg/mL). After placement of scaffolds (Figure 1(c)), the periosteum and skin were approximated and sutured in two layers by resorbable suture (Vicryl 3.0; Ethicon GmbH & Co., KG, Norderstedt, Germany). Thirty minutes before surgery, each dog received a single intramuscular injection of antibiotic (ampicillin 100 mg/kg) and analgesic (morphine 2 mg/kg). The animals were humanely euthanized at 12 weeks postoperatively with vital perfusion-fixation technique through carotid artery [52].

2.4. Radiographic Analysis. Computed tomography (CT) image acquisition was conducted immediately postoperatively for baseline and repeated after 6 and 12 weeks. Dogs were scanned by a high-resolution CT imaging machine (Siemens Somatom Spirit; Berlin, Germany). The effective voxel size was 500 μm and three-dimensional reconstruction of the
images was performed using a “bone mask” in Vitrea Core (v.6.3.2089.106; VITAL, Minnetonka, MN). Bone density was recorded in Hounsfield Unit (HU) within the regions of interest defined within the confines of the defects.

2.5. Histological and Histomorphometric Examination. Mandibular specimens were fixed with 10% formalin (Richard-Allan Scientific, Kalamazoo, MI) for 24 hours at 24°C. After dehydration in ascending concentration of ethanol and clearance in xylene (Sigma-Aldrich), they were embedded in paraffin. The role of sectioning is demonstrated in schematic diagram (Figure 4(a)). Each specimen was divided into three equal sections in which the central part was cut into five-micrometer sections with width parallel to frontal plane. In order to achieve delicate view of histological junction between new bone formed and native bone, distal and proximal parts were cut into five-micrometer sections with width parallel to transverse plane. The sections were stained with hematoxylin and eosin (H&E). The most central sections were analyzed by quantitative histomorphographic assessment of stained slides by a PC-based image analysis system (Image-Pro Plus, Media Cybernetic, Silver Spring, MD). One calibrated examiner determined new bone formation, residual body, soft tissue, and inflammatory elements by polarized light microscopy (Olympus, SZX 9, Tokyo, Japan).

2.6. Statistical Analysis of Data. In order to determine statistically significant differences between the experimental groups, a nonparametric analysis of variance (Kruskal-Wallis) was used. One-way analysis of variance (ANOVA) was used for the comparison of means in histomorphometric quantitation. General linear model of repeated measures was used for comparison of mineralized area and bone density within the groups. After all, Tukey’s test was utilized as the post hoc test at a significance level of 0.05 (SPSS 16, SPSS Inc., Chicago, IL).

3. Results

3.1. Clinical Outcomes. Gross examination of reconstructed defects revealed the presence of a pale yellow fibrous tissue surrounding the previous defect sites in all specimens. The position of screws and plates were stable in all specimens at experimental end-point. The tissues formed within sites grafted with anti-BMP-2 mAb and rhBMP-2 groups appeared to be uniformly solid, compared to control sites which were soft and rubbery.

3.2. Radiographic Analysis. Representative CT imaging data are shown in Figure 2, illustrating qualitative differences among the groups. These 3D reconstructed CT images provide evidence for less defect fill within isotype control mAb group (a1), as compared with anti-BMP-2 mAb and rhBMP-2 groups. The regenerated tissues in site treated with rhBMP-2 appeared to be separated from host bone by a demarcation line (b1). In contrast, the defects treated with anti-BMP-2 showed smooth regeneration without any demarcation line between old and new bone (c1). Comparison of coronal sections (a2, a3, b2, b3, c2, and c3) showed clear differences among the 3 treatment groups. Anti-BMP-2 group showed a homogenous regenerated bone differentiated into medullary and cortical regions, resembling native bone. Although sites treated with rhBMP-2 showed evidence of radiopaque tissue formation, the bone did not exhibit the same level of organization of cortical/cancellous seen in normal host bone. The bone formation in isotype mAb group was attenuated with small noncontiguous islands in some specimens.

Quantitative morphometry was conducted on the CT images and results are shown in Figure 3. These morphometric data at 6 weeks demonstrated increased mineralized bone surface only in positive control rhBMP-2 (108.38 ± 93.8) groups, compared with experimental anti-BMP-2 mAb (43.22 ± 17.88) and isotype-matched negative control group (40.52 ± 14.51). By 12 weeks, mandibular defects treated with anti-BMP-2 mAb (133.92 ± 37.02 mm²) or rhBMP-2 (145.16 ± 76.17 mm²) exhibited increased mineralized bone area, compared with isotype-matched negative control group (46.01 ± 22.25 mm²). The comparison of mean mineralized area showed significant difference between experimental and positive control groups compared with negative control at both time points (p < 0.05). However, there was no statistical difference between anti-BMP-2 mAb and rhBMP-2 groups (p > 0.05) (Figure 2).
Bone densities in anti-BMP-2 mAb, rhBMP-2, and isotype mAb (control) groups were 1360.81 ± 10.52 HU, 1044.27 ± 141.16 HU, and 839.45 ± 179.41 HU at 12th week (Figure 2). The statistical analysis indicated significantly greater bone density in anti-BMP-2 mAb and rhBMP-2 compared with isotype mAb (p < 0.05). However, bone densities were not statistically significantly different in anti-BMP-2 mAb compared to rhBMP-2 treated groups (p > 0.05) (Figure 3).

3.3. Histological and Histomorphometric Analysis. Histological analysis of treated segmental osteotomy defects was carried out and results are shown in Figure 4. Osteotomy defects were divided into proximal, central, and distal portions (Figure 4(a)). Cross sections of the central portion were made to assess de novo bone formation (Figures 4(b), 4(f), and 4(j)). The proximal and distal portions were sectioned horizontally to allow assessment of osteogenesis at the junction...
of host bone and defect sites. Results showed significant de novo bone formation within central portions of sites treated with scaffolds functionalized with anti-BMP-2 mAb (Figure 4(j)) or rhBMP-2 (Figure 4(f)), compared to isotype-matched mAb (Figure 4(b)). The newly formed bone within defects were reconstructed with anti-BMP-2 mAb or rhBMP-2 bridged across the defects continuously from distal to proximal ends. The tissue microstructure showed new osteoid bone formation within defects treated with anti-BMP-2 mAb with mostly lamellar organization, containing osteocytes within lacunae and rimmed with osteoblasts. Bone formation within isotype control specimens was limited to regions immediately adjacent to defect edges, where new bone had formed by apposition on old host bone. Only minimal inflammatory infiltrate was observed, which was mainly superficial in all 3 groups.

Histomorphometric evaluations revealed significantly more osteoid bone formation in anti-BMP-2 mAb (42.99% ± 8.67) and rhBMP-2 (48.97% ± 2.96) groups, compared with isotype mAb (26.8% ± 5.35) (p < 0.05) (Figure 5). Difference of residual scaffold material was not statistically significant among the three groups.

4. Discussion
Since the introduction of the concept of AMOR, the main focus of our research team has been to pursue translational applications of scaffolds functionalized with anti-BMP-2 mAb for repair of major skeletal defects. We have pursued application of anti-BMP-2 in progressively larger animal models in clinically relevant models of skeletal defects. The current study sought to investigate the hypothesis that anti-BMP-2 can mediate repair of continuity mandibular defects. To that end, continuity mandibular defects were created in canine model and repaired with ABBM/collagen scaffold functionalized with chimeric anti-BMP-2 mAb, isotype-matched control mAb (negative control), or rhBMP-2 (positive control). AMOR group mediated 15.19% more bone formation than isotype mAb control group (p < 0.05). AMOR and rhBMP-2 groups did not yield significant differences in bone repair (p > 0.05). These results are consistent with other applications of AMOR and rhBMP-2 in repair of critical size defects [39, 43, 44, 47, 48]. These results are remarkable, when compared with the degree of bone formation achieved after autogenous bone augmentation in mandibular segmental canine model. Sverzut et al. demonstrated 43.35% ± 2.87 in combination of microporous membrane and iliac graft and 60.98% ± 2.38 in iliac graft alone for reconstruction of 10 mm segmental defects [53]. Hussein et al. conducted a study to compare the impact of rhBMP-2 delivery for reconstructing 35 mm long segmental mandibular canine defects after 12 weeks. They showed superior results of bone healing and in agreement with our results the percentage of new bone formation was 52.4% ± 5.6 [54]. However, they reported more complications during their follow-up period.

The presence of bone formation in central sections was the evidence of de novo bone formation. Interestingly, the distal parts showed more bone formation than proximal parts.
Figure 4: Histological examination of specimens at 12 weeks postoperatively. (a) Schematic diagram of the segmental defects, illustrating the location of sections taken for histological analysis. The proximal and distal segments were sectioned horizontally and the cross section of the central segment was taken (b, f, j). (b–m) Representative histomicrographs stained with H&E (40x). (b–e) Isotype-matched mAb, (f–i) rhBMP-2, and (j–m) anti-BMP-2 mAb used to functionalize ABBM-C scaffold. The blue arrows show the junction of newly formed bone and the neighboring host bone. The white arrows show the residual scaffold biomaterials, which were surrounded by connective tissue in control specimens treated with isotype-matched control mAb, while in experimental and positive control specimens the residual scaffold was not easily discernable. Abundant endothelial-lined blood vessels (green arrows) were noted in anti-BMP-2 mAb and rhBMP-2 treated sites.

In all groups. The tissue filling negative control defects were mostly fibrous in nature and constricted in dimensions. Most of the sparsely formed new bone was detected in the center and inferior part of the defect close to the overlying periosteum. The specimens containing rhBMP-2 and anti-BMP-2 revealed very well-formed bony trabeculae, throughout the defect with an active cuboidal osteoblast in the rim. There was direct contact between the original and new bone at the distal and proximal sections of the defect in the experimental group. The morphology of the bone forming within defects in the AMOR group mimicked native bone more closely than rhBMP-2 group. The trabecular pattern observed in
the rhBMP-2 group was predominantly concentrated in the periphery, while in the AMOR group the trabecular pattern was more homogeneously distributed throughout the newly regenerated tissue.

Application of anti-BMP-2 mAb has a number of advantages over administration of exogenous rhBMP-2; for example, (1) there is higher biological activity of endogenous BMP-2 (nearly 10-fold higher) compared with recombinant counterpart [55], hence requiring lower concentrations of BMPs; (2) anti-BMP-2 captures multiple osteogenic endogenous growth factors with which it cross-reacts, including BMP-2, BMP-4, and BMP-7 [47, 48]; and (3) the BMPs captured can be sustained for several weeks in local sites [46–48]. Bone healing can synergistically promote by BMP-4 [56] and BMP-7 [32] in combination with BMP-2 [57]. The efficient dose of rhBMP-2 required for clinical influence is higher than physiological amount [58] and also rhBMP-2 has a short half-life in the body compared to antibodies, that is, 7 min to 2 days for rhBMP2 and 30 to 100 days for antibodies [47].

Radiographic analysis represented higher bone density in anti-BMP-2 mAb group (1360.81 ± 10.52 HU) compared to rhBMP-2 (1044.27 ± 141.16 HU) that is in accordance with our histological results indicating better quality of bone formation in anti-BMP-2 mAb group. Arzi et al. [59] demonstrated regenerated bone in rhBMP-2 group accomplished 46 to 54% of the density of the normal contralateral mandibular bone density after 12 weeks. However, our results showed comparable bone density to normal bone not only in the rhBMP-2 group but also in the anti-BMP-2 mAb group.

Therapeutic antibodies open a new window in regenerative medicine. Dozens of therapeutic monoclonal immunoglobulins are currently in clinical use or under development for the treatment of cancers [60, 61], osteoporosis [62], and immune disorders [60] to bone defects [39, 42–48, 63]. Recent studies showed bone healing enhancement in various bony fractures and defects within animal models [39–48, 63–71]. However, there are many adverse reactions associated with mAb therapy that encompass cytokine release syndrome, serum sickness, and tumor lysis syndrome [72]. Systemic usage of mAbs can vary from local immune reaction in the site of injection to severe anaphylactic shock [72]. In the current study, we applied anti-BMP-2 mAbs locally in which attentive histological analysis failed to find any significant inflammation or other adverse reactions within treated defect sites. In comparison to systemic utilization of Sclerostin mAb for bone healing (25 mg/kg/dose twice weekly for at least 4 weeks) [41, 66], we used noticeably lower concentration of therapeutic mAbs (6.25 μg of total used in each defect). Therefore, application of therapeutic monoclonal antibodies for bone tissue engineering has potentially significant benefits for repair of major skeletal defects. Further investigation is merited prior to clinical application of AMOR.

5. Conclusion

The results of present study made a number of important observations, including (1) evidence of de novo bone formation in a large clinically relevant skeletal defect model, (2) demonstration of the efficacy of anti-BMP-2 for the first time in the canine model, and (3) lack of adverse reaction to the local application of anti-BMP-2 mAb for repair of a large bony defect. The application of anti-BMP-2 mAb in concert with a commonly used scaffold of anorganic bovine bone mineral and collagen yielded successful de novo bone formation to an extent, which was equivalent to that of FDA-approved rhBMP-2, with no evidence of adverse reaction.

Conflicts of Interest

The authors declare no conflicts of interest associated with this research.

References

[1] M. M. Martino, P. S. Briquez, K. Maruyama, and J. A. Hubbell, "Extracellular matrix-inspired growth factor delivery systems for bone regeneration," Advanced Drug Delivery Reviews, vol. 94, pp. 41–52, 2015.
[2] H. Behnia, A. Khojasteh, M. Soleimani, A. Tehranchi, and A. Atashi, "Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: a preliminary report," Journal of Cranio-Maxillo-Facial Surgery, vol. 40, no. 1, pp. 2–7, 2012.
[3] A. Khojasteh, M. B. Eslaminejad, and H. Nazarian, "Mesenchymal stem cells enhance bone regeneration in rat calvarial critical size defects more than platelete-rich plasma," Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontontology, vol. 106, no. 3, pp. 356–362, 2008.
[4] D. H. R. Kempen, L. B. Creemers, J. Alblas et al., "Growth Factor interactions in bone regeneration," Tissue Engineering - Part B: Reviews, vol. 16, no. 6, pp. 551–566, 2010.

[5] S. Stevenson, N. Cunningham, J. Toth, D. Davy, and A. H. Reddi, "The effect of osteogenin (a bone morphogenetic protein) on the formation of bone in orthotopic segmental defects in rats," The Journal of Bone & Joint Surgery, vol. 76, no. 11, pp. 1676–1687, 1994.

[6] T. Kitaori, H. Uto, E. M. Schwarz et al., "Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model," Arthritis & Rheumatism, vol. 60, no. 3, pp. 813–823, 2009.

[7] J. R. Lieberman, A. Daluiski, and T. A. Einhorn, "The role of growth factors in the repair of bone. Biology and clinical applications," The Journal of Bone & Joint Surgery, vol. 84, no. 6, pp. 1032–1044, 2002.

[8] H. Komaki, T. Tanaka, M. Chazono, and T. Kikuchi, "Repair of segmental bone defects in rabbit tibiae using a complex of β-tricalcium phosphate, type I collagen, and fibroblast growth factor-2," Biomaterials, vol. 27, no. 29, pp. 5118–5126, 2006.

[9] D. Wulsten, V. Glatt, A. Ellinghaus et al., "Time kinetics of bone defect healing in response to BMP-2 and GDF-5 characterised by in vivo biomechanics," European Cells & Materials, vol. 21, pp. 177–192, 2011.

[10] P. B. Malafaya, G. A. Silva, E. T. Baran, and R. L. Reis, "Drug delivery therapies I General trends and its importance on bone tissue engineering applications," Current Opinion in Solid State & Materials Science, vol. 6, no. 4, pp. 283–295, 2002.

[11] E. H. Riley, J. M. Lane, M. R. Urist, K. M. Lyons, and J. R. Lieberman, "Bone morphogenetic protein-2: Biology and applications," Clinical Orthopaedics and Related Research, no. 324, pp. 39–46, 1996.

[12] G. Chen, C. Deng, and Y.-P. Li, "TGF-β and BMP signaling in osteoblast differentiation and bone formation," International Journal of Biological Sciences, vol. 8, no. 2, pp. 272–288, 2012.

[13] K. Arvidsson, B. M. Abdalallah, L. A. Applegate et al., "Bone regeneration and stem cells," Journal of Cellular and Molecular Medicine, vol. 15, no. 4, pp. 718–746, 2011.

[14] T. W. Axelrad and T. A. Einhorn, "Bone morphogenetic proteins in orthopaedic surgery," Cytokine & Growth Factor Reviews, vol. 20, no. 5-6, pp. 481–488, 2009.

[15] G. B. Bishop and T. A. Einhorn, "Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery," International Orthopaedics, vol. 31, no. 6, pp. 721–727, 2007.

[16] J. M. Wozney, "Overview of bone morphogenetic proteins," The Spine Journal, vol. 27, no. 16, pp. S2–S8, 2002.

[17] E. A. Wang, V. Rosen, J. S. D’Alessandro et al., "Recombinant human bone morphogenetic protein induces bone formation," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 6, pp. 2220–2224, 1990.

[18] D. I. Israel, J. Nove, K. M. Kerns et al., "Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo," Growth Factors, vol. 13, no. 3-4, pp. 291–300, 1996.

[19] J. T. Koh, Z. Zhao, Z. Wang, I. S. Lewis, P. H. Krebsbach, and R. T. Franceschi, "Combinatorial gene therapy with BMP2/7 enhances cranial bone regeneration," Journal of Dental Research, vol. 87, no. 9, pp. 845–849, 2008.

[20] U. Ripamonti, J. Crooks, J.-C. Petit, and D. C. Rueger, "Peri- odontal tissue regeneration by combined applications of recombinant human osteogenic protein-1 and bone morphogenetic protein-2. A pilot study in Chacma baboons (Papio ursinus)," European Journal of Oral Sciences, vol. 109, no. 4, pp. 241–248, 2001.

[21] M. Zhao, Z. Zhao, J.-T. Koh, T. Jin, and R. T. Franceschi, "Combinatorial gene therapy for bone regeneration: cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4, and 7," Journal of Cellular Biochemistry, vol. 95, no. 1, pp. 1–16, 2005.

[22] A. Aono, M. Hazama, K. Notoya et al., "Potent ectopic bone-inducing activity of bone morphogenetic protein: 4-7 heterodimer," Biochemical and Biophysical Research Communications, vol. 210, no. 3, pp. 670–677, 1995.

[23] V. Rosen, "BMP2 signaling in bone development and repair," Cytokine & Growth Factor Reviews, vol. 20, no. 5-6, pp. 475–480, 2009.

[24] F. Granero-Moltó, J. A. Weis, M. I. Miga et al., "Regenerative effects of transplanted mesenchymal stem cells in fracture healing," Stem Cells, vol. 27, no. 8, pp. 1887–1898, 2009.

[25] S. J. Rodda and A. P. McMahon, "Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors," Development, vol. 133, no. 16, pp. 3231–3244, 2006.

[26] X. Guo and X. Wang, "Signaling cross-talk between TGF-β/BMP and other pathways," Cell Research, vol. 19, no. 1, pp. 71–88, 2009.

[27] T. Komori, H. Yagi, S. Nomura et al., "Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts," Cell, vol. 89, no. 5, pp. 755–764, 1997.

[28] D. Chen, M. Zhao, and G. R. Mundy, "Bone morphogenetic proteins," Growth Factors, vol. 22, no. 4, pp. 233–241, 2004.

[29] S. N. Khan and J. M. Lane, "The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications," Expert Opinion on Biological Therapy, vol. 4, no. 5, pp. 741–748, 2004.

[30] U. M. E. Wikesjö, G. Polimeni, and M. Qahash, "Tissue engineering with recombinant human bone morphogenetic protein-2 for alveolar augmentation and oral implant osseointegration: experimental observations and clinical perspectives.," Clinical Implant Dentistry and Related Research, vol. 7, no. 2, pp. 112–119, 2005.

[31] M. Chin, T. Ng, W. K. Tom, and M. Carstens, "Repair of alveolar clefts with recombinant human bone morphogenetic protein (rhBMP-2) in patients with clefts," The Journal of Craniofacial Surgery, vol. 16, no. 5, pp. 778–789, 2005.

[32] W. Zhu, B. A. Rawlins, O. Boachie-Adjei et al., "Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model," Journal of Bone and Mineral Research, vol. 19, no. 12, pp. 2021–2032, 2004.

[33] E. J. Carragee, E. L. Hurwitz, and B. K. Weiner, "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned," The Spine Journal, vol. 11, pp. 471–491, 2011.

[34] H. Seeherman and J. M. Wozney, "Delivery of bone morphogenetic proteins for orthopedic tissue regeneration," Cytokine & Growth Factor Reviews, vol. 16, no. 3, pp. 329–345, 2005.

[35] S. Elangovan, S. R. D’Mello, L. Hong et al., "The enhancement of BMP and other pathways," Cell Research, vol. 19, no. 4, pp. 323–341, 2009.
[36] T. N. Vo, F. K. Kasper, and A. G. Mikos, “Strategies for controlled delivery of growth factors and cells for bone regeneration,” Advanced Drug Delivery Reviews, vol. 64, no. 12, pp. 1292–1309, 2012.

[37] F. R. A. J. Rose and R. O. C. Orefo, “Bone tissue engineering: hope vs hype,” Biochemical and Biophysical Research Communications, vol. 292, no. 1, pp. 1–7, 2002.

[38] A. Khojasteh, H. Behnia, N. Naghdi, M. Esmaeelinejad, Z. Ali-khassy, and M. Stevens, “Effects of different growth factors and carriers on bone regeneration: A systematic review,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, vol. 116, no. 6, pp. e405–e423, 2013.

[39] A. Moshaverinia, S. Ansari, C. Chen et al., “Co-encapsulation of anti-BMP2 monoclonal antibody and mesenchymal stem cells in alginate microspheres for bone tissue engineering,” Biomaterials, vol. 34, no. 28, pp. 6572–6579, 2013.

[40] H. Chen, X. Xu, M. Liu et al., “Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis,” Bone, vol. 76, pp. 141–148, 2015.

[41] B. A. Tinsley, A. Dukas, M. J. Pensak et al., “Systemic administration of sclerostin antibody enhances bone morphogenic protein-induced femoral defect repair in a rat model,” Journal of Bone and Joint Surgery - American Volume, vol. 97, no. 22, pp. 1852–1859, 2014.

[42] M. O. Freire, H.-K. You, J.-K. Kook, J.-H. Choi, and H. H. Zadeh, “Antibody-mediated osseous regeneration: a novel strategy for bioengineering bone by immobilized anti-bone morphogenic protein-2 antibodies,” Tissue Engineering Part A, vol. 17, no. 23-24, pp. 2911–2918, 2011.

[43] S. Ansari, M. Freire, M. G. Choi et al., “Effects of the orientation of anti-BMP2 monoclonal antibody immobilized on scaffold in antibody-mediated osseous regeneration,” Journal of Biomaterials Applications, vol. 30, no. 5, pp. 558–567, 2015.

[44] S. Ansari, J.-H. Phark, S. Duarte et al., “Biomechanical analysis of engineered bone with anti-BMP2 antibody immobilized on different scaffolds,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol. 104, no. 7, pp. 1465–1473, 2016.

[45] M. Freire, J.-H. Choi, A. Nguyen et al., “Application of AMOR in craniofacial rabbit bone bioengineering,” BioMed Research International, vol. 2015, Article ID 628769, 7 pages, 2015.

[46] S. Ansari, M. O. Freire, E.-K. Pang, A. I. Abdelhamid, M. Almohamdeed, and H. H. Zadeh, “Immobilization of murine anti-BMP-2 monoclonal antibody on various biomaterials for bone tissue engineering,” BioMed Research International, vol. 2014, Article ID 940860, 10 pages, 2014.

[47] S. Ansari, A. Moshaverinia, A. Han, S. H. Pi, A. I. Abdelhamid, and H. H. Zadeh, “Functionalization of scaffolds with chimeric anti-BMP-2 monoclonal antibodies for osseous regeneration,” Biomaterials, vol. 34, no. 38, pp. 10991–10998, 2013.

[48] M. O. Freire, H. K. Kim, J. Kook, A. Nguyen, and H. H. Zadeh, “Antibody-mediated osseous regeneration: the early events in the healing response,” Tissue Engineering Part A, vol. 19, no. 9–10, pp. 1165–1174, 2013.

[49] R. Canceduca, P. Giannoni, and M. Mastrogiacomo, “A tissue engineering approach to bone repair in large animal models and in clinical practice,” Biomaterials, vol. 28, no. 29, pp. 4240–4250, 2007.

[50] W. R. Moore, S. E. Graves, and G. I. Bain, “Synthetic bone graft substitutes,” ANZ Journal of Surgery, vol. 71, no. 6, pp. 354–361, 2001.

[51] J.-Y. Huh, B.-H. Choi, B.-Y. Kim, S.-H. Lee, S.-J. Zhu, and J.-H. Jung, “Critical size defect in the canine mandible,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, vol. 100, no. 3, pp. 296–301, 2005.

[52] A. Martin, H. Gasse, and C. Staszyk, “Absence of lymphatic vessels in the dog dental pulp: An immunohistochemical study,” Journal of Anatomy, vol. 217, no. 5, pp. 609–615, 2010.

[53] C. E. Sverzut, P. E. P. Faria, C. M. Magdalena et al., “Reconstruction of Mandibular Segmental Defects Using the Guided-Bone Regeneration Technique With Polyactide Membranes and/or Autogenous Bone Graft: A Preliminary Study on the Influence of Membrane Permeability,” Journal of Oral and Maxillofacial Surgery, vol. 66, no. 4, pp. 647–656, 2008.

[54] K. A. Hussein, I. E. Zakhary, D. Hailat, R. Elrefai, M. Sharawy, and M. E. Elsalany, “Delayed versus immediate reconstruction of mandibular segmental defects using recombinant human bone morphogenetic protein 2/absorbable collagen sponge,” Journal of Oral and Maxillofacial Surgery, vol. 71, no. 6, pp. 1107–1118, 2013.

[55] K. Beşko, K. Kusumoto, K. Fujimura et al., “Comparison of recombinant and purified human bone morphogenetic protein,” The British Journal of Oral & Maxillofacial Surgery, vol. 37, no. 1, pp. 2–5, 1999.

[56] A. Bandypadhyay, K. Tsuji, K. Cox, B. D. Harfe, V. Rosen, and C. J. Tabin, “Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis,” PLoS Genetics, vol. 2, no. 12, article e216, 2006.

[57] K. Tsuji, A. Bandypadhyay, B. Harfe et al., “BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing,” Nature Genetics, vol. 38, pp. 1424–1429, 2006.

[58] J. M. Wozney, V. Rosen, A. J. Celeste et al., “Novel regulators of bone formation: Molecular clones and activities,” Obstetrical & Gynecological Survey, vol. 44, no. 5, pp. 387–388, 1989.

[59] B. Arzi, F. J. M. Verstraete, D. J. Huey, D. D. Cissell, and K. A. Athanasiou, “Regenerating Mandibular Bone Using rhBMP-2: Part 1-Immediate Reconstruction of Segmental Mandibular Defects,” Veterinary Surgery, vol. 44, no. 4, pp. 403–409, 2015.

[60] P. Chames, M. van Regemortel, E. Weiss, and D. Baty, “Therapeutic antibodies: successes, limitations and hopes for the future,” British Journal of Pharmacology, vol. 157, no. 2, pp. 220–233, 2009.

[61] A. M. Scott, J. D. Wolchok, and L. J. Old, “Antibody therapy of cancer,” Nature Reviews Cancer, vol. 12, no. 4, pp. 278–287, 2012.

[62] V. Heath, “Pharmacotherapy: Novel antibody therapy demonstrates potential for building bone in osteoporosis,” Nature Reviews Endocrinology, vol. 10, no. 3, p. 125, 2014.

[63] Y. Zhao, J. Zhang, X. Wang et al., “The osteogenic effect of bone morphogenetic protein-2 on the collagen scaffold conjugated with antibodies,” Journal of Controlled Release, vol. 141, no. 1, pp. 30–37, 2010.

[64] P. K. Suen, T. Y. Zhu, D. H. K. Chow, L. Huang, L.-Z. Zheng, and L. Qin, “Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats,” Scientific Reports, vol. 5, Article ID 15632, 2015.

[65] G. Feng, Z. Chang-Qing, C. Yi-Min, and L. Xiao-Lin, “Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats,” International Immunopharmacology, vol. 24, no. 1, pp. 7–13, 2015.

[66] F. Aalee, M. S. Virk, H. Tang et al., “Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody
on bone repair in a rat femoral defect model,” *Journal of Orthopaedic Research*, vol. 32, no. 2, pp. 197–203, 2014.

[67] A. M. Makhdom, F. Rauch, D. Lauzier, and R. C. Hamdy, ”The effect of systemic administration of sclerostin antibody in a mouse model of distraction osteogenesis,” *Journal of Musculoskeletal and Neuronal Interactions*, vol. 14, no. 1, pp. 124–130, 2014.

[68] M. S. Ominsky, Q.-T. Niu, C. Li, X. Li, and H. Z. Ke, ”Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody,” *Journal of Bone and Mineral Research*, vol. 29, no. 6, pp. 1424–1430, 2014.

[69] P. K. Suen, Y.-X. He, D. H. K. Chow et al., ”Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats,” *Journal of Orthopaedic Research*, vol. 32, no. 8, pp. 997–1005, 2014.

[70] L. Cui, H. Cheng, C. Song et al., ”Time-dependent effects of sclerostin antibody on a mouse fracture healing model,” *Journal of Musculoskeletal and Neuronal Interactions*, vol. 13, no. 2, pp. 178–184, 2013.

[71] M. S. Ominsky, C. Li, X. Li et al., ”Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones,” *Journal of Bone and Mineral Research*, vol. 26, no. 5, pp. 1012–1021, 2011.

[72] T. T. Hansel, H. Kropshofer, T. Singer, J. A. Mitchell, and A. J. T. George, ”The safety and side effects of monoclonal antibodies,” *Nature Reviews Drug Discovery*, vol. 9, no. 4, pp. 325–338, 2010.